Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E36.98 EPS (ttm)1.63 Insider Own1.80% Shs Outstand1.66B Perf Week-2.90%
Market Cap99.97B Forward P/E35.16 EPS next Y1.71 Insider Trans-1.70% Shs Float1.66B Perf Month1.48%
Income2.72B PEG2.99 EPS next Q0.41 Inst Own72.10% Short Float1.65% Perf Quarter11.98%
Sales16.06B P/S6.22 EPS this Y32.80% Inst Trans0.08% Short Ratio4.02 Perf Half Y20.66%
Book/sh9.13 P/B6.60 EPS next Y-4.72% ROA7.80% Target Price60.42 Perf Year22.72%
Cash/sh4.35 P/C13.84 EPS next 5Y12.38% ROE17.80% 52W Range45.35 - 64.44 Perf YTD2.10%
Dividend1.48 P/FCF93.09 EPS past 5Y-3.60% ROI10.70% 52W High-6.47% Beta0.31
Dividend %2.46% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin74.40% 52W Low32.90% ATR1.29
Employees28000 Current Ratio1.70 Sales Q/Q-3.50% Oper. Margin22.50% RSI (14)45.74 Volatility2.25% 2.04%
OptionableYes Debt/Eq0.51 EPS Q/Q2.40% Profit Margin16.90% Rel Volume1.21 Prev Close61.14
ShortableYes LT Debt/Eq0.48 EarningsJan 27 BMO Payout87.20% Avg Volume6.77M Price60.27
Recom2.40 SMA20-1.48% SMA500.70% SMA20015.26% Volume8,225,714 Change-1.42%
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
Sep-22-10Reiterated Deutsche Bank Buy $28 → $31.50
Sep-01-10Reiterated UBS Neutral $26 → $27
Aug-31-10Upgrade Jefferies Hold → Buy $28.80 → $30
Jan-30-15 05:25PM  Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog Zacks
03:59PM  US profitability: the rich list at Financial Times
Jan-29-15 05:19PM  U.S. Food and Drug Administration Approves Bristol-Myers Squibbs Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults Business Wire
08:00AM  Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors GlobeNewswire
Jan-28-15 10:10AM  Company News for January 28, 2015 - Corporate Summary Zacks
Jan-27-15 06:10PM  Drug Firms Report Good Q4, But Outlook Cloudy at Investor's Business Daily
06:00PM  Cramer: I've never seen anything like this CNBC
05:31PM  Updates, advisories and surprises at MarketWatch
02:39PM  Strong Dollar Means Flabby Outlook For Some Overseas at Investor's Business Daily
01:48PM  Cancer Drugs Boost Bristol-Myers Sales at The Wall Street Journal
01:05PM  Midday movers: Lockheed Martin, Plantronics & more at CNBC
12:42PM  Bristol-Myers Squibb (BMY) Stock Falls Today on Weak Guidance at TheStreet
11:57AM  Bristol, Pfizer, Novartis Forecasts Face FX Pressures at Investor's Business Daily
11:09AM  Pfizer Edges Ahead On Q4, Even As Forecast Falls Short at Barrons.com
10:51AM  Bristol-Myers Beats on Q4 Earnings, 2015 View Disappoints - Analyst Blog Zacks
09:29AM  Bristol-Myers says strong dollar drags on 2015 outlook Reuters
09:11AM  Bristol-Myers issues cautious 2015 forecast due to strong dollar Reuters
08:44AM  Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues - Tale of the Tape Zacks
08:38AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
08:06AM  Bristol-Meyers beats fourth quarter expectations, but stock dips after dissappointing outlook at MarketWatch
07:58AM  Pension charge, lower sales slash Bristol-Myers' Q4 profit AP
07:56AM  Bristol-Myers quarterly profit beats forecasts Reuters
07:56AM  Bristol-Myers beats Street 4Q forecasts AP
07:33AM  Bristol-Myers 2015 Sales Forecast Stymied by Dollars Strength at Bloomberg
07:30AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results Business Wire
07:07AM  Q4 2014 Bristol-Myers Squibb Co Earnings Release - Before Market Open CCBN
Jan-26-15 04:45PM  CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog Zacks
03:29PM  What to Expect When Bristol-Myers Squibb (BMY) Reports Fourth-Quarter Earnings Tomorrow at TheStreet
06:47AM  Cramer: Don't Be Afraid of the Greek Vote TheStreet
Jan-23-15 04:34PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem EDGAR Online
03:50PM  Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - Analyst Blog Zacks
06:15AM  Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals
Jan-22-15 07:44PM  Lightning Round: Only private equity I recommend at CNBC
Jan-21-15 06:13PM  Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog Zacks
11:46AM  The Lone Biotech Bear? at Forbes
06:33AM  p53, Immunology and Antibody Drug Conjugate Therapies Bringing More Powerful Weapons to Battlefield in the War on Cancer Company Spotlight
Jan-20-15 08:17PM  Bristol-Myers Operating Chief to Become CEO in May at The Wall Street Journal
07:26PM  Bristol-Myers Squibb CEO steps down, replaced by COO at Fortune
06:17PM  Bristol-Myers Operating Chief to Become CEO at The Wall Street Journal
05:47PM  Bristol-Myers names Caforio as CEO AP
05:29PM  Bristol-Meyers Squibb taps a doctor as new CEO at CNBC
05:22PM  Bristol-Myers taps insider Caforio as next CEO Reuters
04:52PM  Bristol-Myers Names New CEO at Barrons.com
04:40PM  Bristol-Myers Squibb names Giovanni Caforio CEO, effective May 5 at MarketWatch
04:38PM  Bristol-Myers Names New CEO as Andreotti Becomes Chairman at Bloomberg
04:35PM  Bristol-Myers Squibb gets new CEO CNBC
04:30PM  Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman Business Wire
01:37PM  Investing in the Next Apple: 4 Boring But Innovative Companies to Buy Now at TheStreet
Jan-16-15 09:17AM  Jim Cramer on Europe and Why He's an 'America First' Stock Picker at TheStreet
Jan-15-15 06:14PM  Cramer: Forget Switzerland! Make big bucks in USA at CNBC
11:02AM  Eli Lilly Has 'Turned The Corner,' Upgraded at Investor's Business Daily
09:01AM  Cramer: Swiss move traumatizing CNBC
06:45AM  Stakes High for AstraZeneca Heart Drug Facing Tough Competition at Bloomberg
Jan-14-15 05:35PM  Eli Lilly Inks Oncology Deals with Merck, Bristol-Myers - Analyst Blog Zacks
07:55AM  A New Dawn For Biotech? at Forbes
Jan-13-15 11:42AM  Bristol-Myers Squibb (BMY) Stock Rises Today After Eli Lilly Collaboration at TheStreet
08:52AM  Lilly to Collaborate on Cancer Drug Trials at The Wall Street Journal
08:00AM  Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors Business Wire
06:00AM  'Mad Money' Lightning Round: Hold Onto WhiteWave, Bristol-Myers at TheStreet
Jan-12-15 07:04PM  Lightning Round: Sweet spot of the marketplace at CNBC
06:23PM  Your first trade for Tuesday at CNBC
05:58PM  Fast Money Final Trade: TIF, SNDK, FRO & BMY CNBC
04:25PM  The Top Ten Stocks for Jan. 12 at Bloomberg
03:34PM  Merck, Bristol heat up immunotherapy race in lung cancer Reuters
03:13PM  Bristol's Lung Cancer Drug Aces Trial, Cheers Bulls at Barrons.com
02:25PM  Bristol-Myers Hits 14-Year High On Cancer Drug Trial at Investor's Business Daily
11:05AM  Bristol-Myers' stock jumps on lung-cancer drug success AP
09:38AM  [$$] Bristol-Myers's Lung Cancer Drug Shows Success at The Wall Street Journal
09:35AM  What We're Trading Yahoo Finance Blogs
08:58AM  Bristol-Myers Shares Gain on Lung Cancer Treatment Study Results at Bloomberg
08:17AM  Bristol-Myers Squibb jumps on Opdivo cancer drug test at MarketWatch
08:00AM  Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris┬« (Brentuximab Vedotin) and Opdivo┬« (Nivolumab) in Hematologic Malignancies Business Wire
07:26AM  Ahead of the Bell: Drugmaker Bristol-Myers' stock jumps AP
07:07AM  Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival at TheStreet
Jan-11-15 10:33PM  Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint Reuters
09:06PM  CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early Business Wire
Jan-09-15 10:46AM  Harvard Professors Balk As Obamacare Comes To Cambridge at Forbes
Jan-08-15 07:50PM  FDA Approves New Oral Anticoagulant From Daiichi Sankyo at Forbes
07:15PM  Cramer Remix: Party with these rock star stocks at CNBC
06:58PM  U.S. FDA approves Daiichi anti-clotting drug Reuters
Jan-07-15 11:44AM  Adaptive Buys Sequenta to Disrupt Cancer Diagnosis, Drug Discovery at Forbes
Jan-06-15 09:30AM  Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference Business Wire
Jan-05-15 08:00AM  Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases Business Wire
Jan-01-15 03:36PM  A blueprint for health? at Financial Times
Dec-31-14 01:15PM  5 Biotech Stocks With Big News Due In January at Investor's Business Daily
Dec-29-14 12:37PM  Bristol-Myers traders see limited upside optionMONSTER
06:00AM  Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens at TheStreet
Dec-26-14 12:54PM  Pharma Firms Have Plenty of Ammo for Another Big M&A Year in 2015 at The Wall Street Journal
12:35PM  4 Potential Blockbuster Drugs The FDA Just Approved at Investor's Business Daily
Dec-24-14 06:00AM  [video]'Mad Money' Lightning Round: SunTrust Banks Is Terrific at TheStreet
Dec-23-14 09:15PM  Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square at BusinessWeek
09:56AM  [video] Strong GDP Report Could Push Dow to New Record at MarketWatch
09:45AM  Tue. Dec. 23: Watch Walgreen Stock at MarketWatch
09:21AM  Keurig shares fall after recall; Walgreen jumps on strong profits; Family Dollar delays votes on Dollar Tree buyout Hot Stock Minute
08:51AM  U.S. stocks: Dow industrials on track to top 18,000 at MarketWatch
07:56AM  Dow tops 18,000 on strong GDP report Hot Stock Minute
12:33AM  PRESS DIGEST- Wall Street Journal - Dec 23 Reuters
12:18AM  U.S. Approves Skin Cancer Treatment at The Wall Street Journal
Dec-22-14 05:42PM  Steelcase shares slide as revenue comes in light at MarketWatch
05:21PM  Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM